Celldex TherapeuticsCLDX -0.94%57 Net Debt Paydown Yield % is 0.02% as of Jul. 01, 2026, which is at its 10-year median of 0.02. GuruFocus rates CLDX with a GF Score™ of 57/100 and a GF Value™ of $7.04 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,162 Biotechnology companies, Celldex Therapeutics ranks worse than 51.2% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Celldex Therapeutics's Net Debt Paydown Yield % was 0.02%.
Celldex Therapeutics (NAS:CLDX) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Celldex Therapeutics Net Debt Paydown Yield % Related Terms
Celldex Therapeutics Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Celldex Therapeutics's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celldex Therapeutics Net Debt Paydown Yield % Chart
CLDX vs TARS, KLRA, IRON: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Celldex Therapeutics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celldex Therapeutics Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Celldex Therapeutics's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.02% mean?
Celldex Therapeutics (CLDX) has a Net Debt Paydown Yield % of 0.02% as of Jul. 01, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Celldex Therapeutics and its competitors. This is near median its historical median of 0.02. According to the industry distribution chart, Celldex Therapeutics ranks #595 out of 1162 companies in the Biotechnology industry, placing it in the top 51.2%.
Is Celldex Therapeutics' Net Debt Paydown Yield % too high?
Celldex Therapeutics' current Net Debt Paydown Yield % of 0.02% is near median its 10-year median of 0.02. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. Celldex Therapeutics' value of 0.02% is 33.3% below this industry median. Based on the distribution chart, Celldex Therapeutics ranks #595 out of 1162 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Net Debt Paydown Yield % compare to TARS and KLRA?
According to the Biotechnology industry distribution chart, Celldex Therapeutics ranks #595 out of 1162 companies for Net Debt Paydown Yield %. This places Celldex Therapeutics in the lower half of its industry. The industry median Net Debt Paydown Yield % is 0.03. Celldex Therapeutics' value of 0.02% is 33.3% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.03, Celldex Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,162 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celldex Therapeutics's current Net Debt Paydown Yield % of 0.02% is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Celldex Therapeutics and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celldex Therapeutics's current Net Debt Paydown Yield % is 0.02%, which is near median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.04, compared to a current price of $36.86 — trading 423.6% above its estimated fair value. The current Net Debt Paydown Yield % is 0.02%, which is near median its 10-year median of 0.02 and 33.3% below the Biotechnology industry median of 0.03. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current Net Debt Paydown Yield % is 0.02% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celldex Therapeutics (CLDX) Overvalued in 2026?
Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued.
The current stock price of $36.86 is trading 423.6% above its estimated GF Value™ of $7.04.
GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.
Key valuation signals for CLDX:
Net Debt Paydown Yield %: 0.02% (near median its 10-year median of 0.02)
GF Value™: $7.04 vs. price of $36.86 (423.6% above fair value)
Industry Position: 33.3% below the Biotechnology median (#595 of 1162)
No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score
Get the complete analysis for CLDX
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDX has been successfully added to your 
